Rational drug use in the treatment of depression

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 45-61

  Cohen, Lawrence J ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CARBAMAZEPINE; DESIPRAMINE; DEXAMPHETAMINE; DOXEPIN; FLUDROCORTISONE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TOLBUTAMIDE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BLEEDING; CLINICAL PROTOCOL; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; MUSCLE CRAMP; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031033949     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (201)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM IHR psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
2. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl 5):28-34.
3. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
4. Richelson E. Synaptic pharmacology of antidepressants: an update. McLean Hosp J 1988;13:67-88.
5. Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:183-93.
6. Robinson DS, Cerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind, placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-9.
7. Potter WZ, Manji HK, Rudorfer MV. Tricyclics and tetracyclics. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:141-60.
8. Charney DS, Miller HL, Licinio J, Salomon R. Treatment of depression. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:575-601.
9. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-25.
10. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55(suppl 12):3-15.
11. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-30.
12. Skaer TL, Sclar DA, Robison LM, Galin RS, Legg RF, Nemic NL. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995;56:556-67.
13. Saklad SR. Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy 1995;15(6 Pt 2):76S-83.
14. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310: 1433-8.
15. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-42.
16. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
17. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):191-25.
18. Leonard BE. New approaches to the treatment of depression. J Clin Psychiatry 1996;57(suppl 4):26-33.
19. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-9.
20. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54(suppl 2):16-22.
21. Isacsson G, Böethius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992;85:444-8.
22. Kupfer DJ. Management of recurrent depression. J Clin Psychiatry 1993;54(suppl 2):29-33.
23. Alexanderson B, Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;4:764-8.
24. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
25. Brown CS, Wells BO, Self TH, et al. Influence of carbamazepine on plasma imipramine concentration in children with attention-deficit disorder [abstr 122E]. Pharmacotherapy 1988;8:135.
26. Ciraulo DA, Alderson LM, Chapron DJ, et al. Imipramine disposition in alcoholics. J Clin Psychopharmacol 1982;2:2-7.
27. Ciraulo DA, Barnhill JG, Jaffe JH. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 1988;43:509-18.
28. Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther 1984;35:183-7.
29. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. Drug interaction between sertraline and desipramine or imipramine. J Clin Pharmacol 1994;34:1030.
30. Miller DD, Sawyer JB, Duffy JP. Cimetidine's effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm 1983;17:904-5.
31. Silverman G, Braithwaite R. Interaction of benzodiazepines with tricyclic antidepressants. Br Med J 1972;4:111.
32. Abramowicz M, ed. Methylphenidate (Ritalin). Med Lett Drugs Ther 1969;11:47-8.
33. Drimmer EJ, Gitlin MJ, Gwirtsman HE. Desipramine and methylphenidate combination treatment for depression: case report. Am J Psychiatry 1983;140:241-2.
34. Garrettson LK, Perel JM, Dayton PG. Methylphenidate interactions with both anticonvulsants and ethyl biscoumacetate. JAMA 1969;207:2053-6.
35. Beaumont G. Drug interactions with clomipramine (Anafranil). J Clin Med Res 1973;1:480.
36. Ragheb M. Drug interactions in psychiatric practice. Int Pharmacopsychiatry 1981;16:92-118.
37. Abramowicz M, ed. Nefazodone for depression. Med Lett Drugs Ther 1995;37:33-5.
38. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.
39. Koenig HG. Depressive disorders in older medical inpatients. Am Fam Physician 1991;44:1243-50.
40. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(suppl 8):3-15.
41. Schatzberg AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991;52(suppl 5):14-20.
42. Kehoe WA, Schorr RB. Focus on mirtazapine: a new antidepressant with noradrenergic and specific serotonergic activity. Formulary 1996;31:455-69.
43. Depression Guideline Panel. Depression in primary care, vol 2. Treatment of major depression. Clinical practice guideline no. 5. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1993.
44. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524-34.
45. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-37.
46. Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Arch Gen Psychiatry 1991;48:319-23.
47. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990;47: 935-41.
48. Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives. Arch Gen Psychiatry 1989;46:787-93.
49. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-11.
50. Sheehan DV, Claycomb BJ, Kouretas N. Monoamine oxidase inhibitors: prescription and patient management. Int J Psychiatry Med 1980-1981;10:99-121.
51. McElroy SL, Keck PE Jr, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995;56(suppl 2):49-55.
52. Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990;51(suppl 1):21-6.
53. Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry 1996;56:99-104.
54. Salzman C. Antidepressants. Clin Geriatr Med 1990;6: 399-410.
55. Parke-Davis, Division of Warner-Lambert Co. Nardil (phenelzine) package insert. Morris Plains, NJ; 1994.
56. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:161-82.
57. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
58. Keck PE Jr, Hudson JI, Dorsey CM, Campbell PI. Effect of fluoxetine on sleep [letter]. Biol Psychiatry 1991;29:618-25.
59. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 1986;22:97-9.
60. Saletu B, Frey R, Krupka M, Anderer P, Grünberger J, See WR. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991;14:439-47.
61. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995,18:470-7.
62. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
63. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1993;54:71.
64. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-8.
65. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychol 1995;37:336-7.
66. Altshuler LL, Pierre JM, Wirshing WC, Ames D. Sertraline and akathisia. J Clin Psychopharmacol 1994;14:278-9.
67. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine, and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6:51-8.
68. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989;146:1352-3.
69. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine [letter]. Am J Psychiatry 1991;148:1403.
70. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-82.
71. Fallon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 1991; 11:147-8.
72. Friedman EH. Fluoxetine-induced akathisia in male OCD patients. J Clin Psychiatry 1990;51:212.
73. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry' 1989;50:339-42.
74. Maany I, Dhopesh V. Akathisia and fluoxetine. J Clin Psychiatry 1990;51:210-12.
75. Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine: a new antidepressant. J Neural Transm 1979;45:165-75.
76. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52:491-3.
77. Fleischhacker WW. Propranolol for fluoxetine-induced akathisia. Biol Psychiatry 1991;30:526-32.
78. Aranth J, Lindberg C. Bleeding: a side effect of fluoxetine [letter]. Am J Psychiatry 1992;149:412.
79. Berk M, Jacobson BF, Hurly E. Fluoxetine and hemostatic function: a pilot study. J Clin Psychiatry 1995;56:14-16.
80. Humphries JE, Wheby MS, Vanden Berg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990;114:727-8.
81. Evans TG, Buys SS, Rodgers GM. Letter to the editor. N Engl J Med 1991;324:1671.
82. Ottervanger JP, Stricker BH, Huls J, Weeda JN. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994;151:781-2.
83. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991;148:949.
84. Guze BH, Gitlin M. New antidepressants and the treatment of depression. J Fam Pract 1994;38:49-57.
85. Greb WH, Buscher G, Dierdorf HD, Köster FE, Wolf D, Mellows G. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand 1989;80(suppl 350):95-8.
86. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 1987;7:36S-43.
87. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, 1: Antidepressants and antipsychotics. J Clin Psychopharmacol 1990;10:48-50.
88. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, II. J Clin Psychopharmacol 1990;10:213-17.
89. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988;2:850-1.
90. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97(suppl 6A):24S-32.
91. Wehr TA, Goodwin FK. Do antidepressants cause mania? Psychopharmacol Bull 1987;23:61-5.
92. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-11.
93. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-9.
94. De Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252-6.
95. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991;83:188-92.
96. Pope HG, McElroy S, Nixon R. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988;145:1292-4.
97. Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990;51:344-5.
98. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989;146:278.
99. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 1989;146:1515.
100. Ball S, Ahern D, Kao J, Scatina J. Venlafaxine: effects on CYP 2D6 dependent imipramine and desipramine 2-hydroxylation; comparative studies with fluoxetine and effects on CYP 1A2, CYP 3A4, and CYP 2C9 [abstr]. Clin Pharmacol Ther 1996;59:170.
101. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
102. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(6 Pt 2):84S-99.
103. Brøsen K, Hansen JG, Nielsen KK, Sindru SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
104. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP 2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
105. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15:243-6.
106. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
107. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. Are poor metabolizers of sparteine/debrisoquin less pain tolerant than extensive metabolizers? Pain 1993;53:335-49.
108. Anonymous. Physician drug and diagnosis audit. Newtown, PA: Scott-Levin Associates, 1994.
109. Roberts SM, Harbison RD, James RC. Human microsomal N-oxidative metabolism of cocaine. Drug Metab Dispos 1991;19:1046-51.
110. Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate, and phenytoin. Epilepsy Res 1991;10:201-4.
111. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
112. Solvay Pharmaceuticals. Luvox (fluvoxamine) prescribing information. Marietta, GA; 1995.
113. Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995;58:269-78.
114. Janssen Pharmaceuticals. Data on file. Nizoral and Claritin interactions warning. Titusville, NJ; 1993.
115. Affrime MB, Lorber R, Danzig M, Cuss F, Brannan MD. Three-month evaluation of electrocardiographic effects of loratadine in humans [abstr]. J Allergy Clin Immunol 1993;91:259.
116. Roerig Pharmaceuticals. Zoloft (sertraline) prescribing information. New York, NY; 1995.
117. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand 1989;80(suppl 250):102-6.
118. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-6.
119. Perucca E, Gatti G, Cipolla C, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
120. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45;1211-14.
121. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15:237-49.
122. Diot P, Jonville AP, Gerard F, et al. Possible interaction entre theophylline et fluvoxamine. Therapie 1991;46:170-1.
123. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Mol Pharmacol 1993;43;827-32.
124. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
125. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991;6:460-2.
126. Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients; Int J Clin Pharmacol Res 1993;13:167-71.
127. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M. Interaction between fluvoxamine and theophylline. Pharm J 1992;August:137.
128. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
129. Devane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55(suppl 12):38-45.
130. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(12 suppl B):28-33.
131. Gregor KJ, Overhage JM, Coons SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994;16:306-15.
132. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12 suppl B):18-27.
133. Reimherr FW, Byerley WF, Ward MF, Lebegue BJ, Wender PH. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 1988;24:200-5.
134. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am J Hosp Pharm 1994;51:2279-81.
135. Berlin CS. Fluoxetine withdrawal symptoms [letter]. J Clin Psychiatry 1996;57:93-4.
136. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-9.
137. Einbinder E. Fluoxetine withdrawal? [letter] Am J Psychiatry 1995;152:1235.
138. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolphi ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol 1994;14:206-7.
139. Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation [letter]. Am J Psychiatry 1994;151:450-1.
140. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? [letter] Biol Psychiatry 1993;33:851-2.
141. Szabadi E. Fluvoxamine withdrawal syndrome [letter]. Br J Psychiatry 1992;160:283-4.
142. Bloch M, Stager SV, Braun AR, Rubinow DR. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995;346:57.
143. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289.
144. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
145. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995(suppl 6):12-21.
146. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983;44:197-201.
147. Settle EC Jr. Bupropion, a novel antidepressant - update 1989. Int Drug Ther Newslett 1989;24:30-6.
148. Fleet JV, Manberg PJ, Miler LL, et al. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983;44:191-6.
149. Nofzinger EA, Reynolds CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995;152:274-6.
150. Golden RN, Bebchuk JM, Leatherman ME. Trazodone and other antidepressants. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:195-213.
151. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990;51(suppl 9):13-17.
152. Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994;17:544-50.
153. van Bemmel AL, Havermans RG, van Diest R. Effect of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology 1992;107:569-74.
154. Jones D, Gershon S, Sitaram N, Keshavan M. Sleep and depression. Psychopathology 1987;20(suppl 1):20-31.
155. Banos JE, Bosch F, Farré M. Drug-induced priapism. Its aetiology, incidence, and treatment. Med Toxicol 1989;4:46-58.
156. Bardin ED, Krieger JN. Pharmacological priapism: comparison of trazodone-and papaverine-associated cases. Int Urol Nephrol 1990;22:147-52.
157. Hanno PM, Lopez R, Wein AJ. Trazodone-induced priapism. Br J Urol 1988;61:94-100.
158. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990;51:430-3.
159. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry 1987;48:244-5.
160. Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1993;16(suppl 1):S45-50.
161. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D'Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-21.
162. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-41.
163. Bristol-Myers Squibb Pharmaceuticals. Serzone (nefazodone) prescribing information. Princeton, NJ; 1995.
164. Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994;10:123-7.
165. Sharpley AL, Walsh AES, Cowen PJ. Nefazodone a novel antidepressant may increase REM sleep. Biol Psychiatry 1992;31:1070-3.
166. Greene DS, Dockens RC, Salazar DE, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines. I. Pharmacokinetic assessment [abstr PI-74]. Clin Pharmacol Ther 1994;55:141.
167. Woosley RL, Chen Y, Freiman J, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
168. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54: 119-26.
169. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
170. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9.
171. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
172. Clerc GE, Ruimy P, Verdeau-Paillès J, et al. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
173. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9 suppl A):62-8.
174. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors [abstr PI-71]. Clin Pharmacol Ther 1994;55:141.
175. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-71.
176. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-6.
177. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9.
178. FDC Reports. Organon Remeron phase IV trial to examine somnolence. Pink Sheet 1996(June 24):T&G 3-4.
179. Ruigt GSF, Kemp B, Groenhout CM, Kamphuisen HAC. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-4.
180. 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 1989;97:115-17.
181. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.
182. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(suppl 12):61-9.
183. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry 1994;52(suppl 2):20-6.
184. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-9.
185. Munoz RF, Hollon SD, McGrath E, Rehm LP, VandenBos GR. On the AHCPR depression in primary care guidelines. Further considerations for practitioners. Agency for Health Care Policy and Research (AHCPR). Am Psychiatry 1994;49:42-61.
186. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55(9 suppl A):55-9.
187. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:377-8.
188. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983;40:1335-42.
189. Nelson JC, Byck R. Rapid response to lithium in phenelzine nonresponders. Br J Psychiatry 1982;141:85-6.
190. O'Flanagan PM. Clomipramine infusion and lithium carbonate: a synergistic effect? [letter] Lancet 1973;2:974.
191. Price LH, Charney DC, Heninger GR. Variability of response of lithium augmentation in refractory depression. Am J Psychiatry 1986;143:1387-92.
192. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-9.
193. Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-8.
194. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969;126:457-69.
195. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241-6.
196. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13:305-11.
197. Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989;4(suppl 1):37-40.
198. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-4.
199. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
200. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-9.
201. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of a cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995;31: 249-58.